M.R. Meijerink

M.R. Meijerink is a prominent clinical research entity and consultancy led by Professor Martijn R. Meijerink, a world-renowned interventional radiologist at Amsterdam UMC. The organization specializes in the development and clinical validation of advanced image-guided tumor ablation technologies, including Irreversible Electroporation (IRE), Microwave Ablation (MWA), and Radiofrequency Ablation (RFA). M.R. Meijerink serves as the lead sponsor and principal investigator for several landmark international clinical trials, most notably the COLLISION and CROSSFIRE trials, which evaluate ablation techniques against standard-of-care surgery and radiotherapy in pancreatic and colorectal cancers. The entity is also at the forefront of 'immuno-ablation' research, investigating the synergistic effects of combining local thermal or non-thermal ablation with immunotherapy agents like checkpoint inhibitors and novel adjuvants.